- Poster presentation
- Open Access
- Published:
The fate of orally available antimicrobials
BMC Proceedings volume 5, Article number: P44 (2011)
Introduction / objectives
Changing an antimicrobial treatment regimen has shown to influence the occurrence of antimicrobial resistance, with regimen consisting of the dose, the treatment interval, the duration of therapy, and the route of administration of the drug. For concentration dependent antimicrobials there is substantial evidence to encourage the use of a high dose, with regular treatment interval and short course to minimise the risk for the selection of resistant mutants. However, in contrast with these first three aspects of the antimicrobial treatment regimen, little attention is currently paid to the influence of route of administration for the probability of selection and spread of resistant strains.
Methods
By comparing data from different animal species, the purpose is to explore the different routes of administration with regard to the stimulation of antimicrobial resistance.
Results
A historical review on the emergence of resistance to beta-lactamas and tetracycline in Staphylococcus aureus and Escherichia coli in different animal species and humans will be provided. Data on commonly used treatment regimens for humans and animal will be compared and the potential impact on selection, co-selection and spread of resistance will be discussed escriptively. Special attention will be given to the difference in resistance development between topical, oral, and parenteral administration of antimicrobial agents.
Conclusion
Attention to the route of administration might be an underestimated approach to mitigate the risk of selection for pathogens resistant to antimicrobials in both human and veterinary medicine.
Disclosure of interest
None declared.
Author information
Authors and Affiliations
Rights and permissions
Open Access This article is published under license to BioMed Central Ltd. This is an Open Access article is distributed under the terms of the Creative Commons Attribution License ( https://creativecommons.org/licenses/by/2.0 ), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
About this article
Cite this article
Catry, B., Persoons, D. & Dewulf, J. The fate of orally available antimicrobials. BMC Proc 5 (Suppl 6), P44 (2011). https://doi.org/10.1186/1753-6561-5-S6-P44
Published:
DOI: https://doi.org/10.1186/1753-6561-5-S6-P44
Keywords
- Public Health
- Escherichia Coli
- Treatment Regimen
- Tetracycline
- Staphylococcus Aureus